About Me
Uroosa Ibrahim, MD, is Assistant Professor of Medicine (Hematology and Medical Oncology) and Associate Medical Director of the Cellular Therapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. She is Medical Director of the Bone Marrow Transplant Unit and serves as a member of the Bone Marrow Transplant Disease Focus Group at The Tisch Cancer Institute.
Dr. Ibrahim’s clinical and research focus is on cellular therapy (CAR T cell therapy) and optimization of allogeneic stem cell transplant for the management of patients with hematologic malignancies. She is the site principal investigator for numerous multi-center clinical trials studying new therapeutic approaches. Dr. Ibrahim serves on multiple committees of the Center for International Blood and Marrow Transplant Research related to cellular therapy and their toxicities, acute leukemia, and lymphoproliferative disorders.
Dr. Ibrahim is on Twitter at @uroosaibrahim
Language
Position
ASSISTANT PROFESSOR | Medicine, Hematology and Medical OncologyHospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
About Me
Uroosa Ibrahim, MD, is Assistant Professor of Medicine (Hematology and Medical Oncology) and Associate Medical Director of the Cellular Therapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. She is Medical Director of the Bone Marrow Transplant Unit and serves as a member of the Bone Marrow Transplant Disease Focus Group at The Tisch Cancer Institute.
Dr. Ibrahim’s clinical and research focus is on cellular therapy (CAR T cell therapy) and optimization of allogeneic stem cell transplant for the management of patients with hematologic malignancies. She is the site principal investigator for numerous multi-center clinical trials studying new therapeutic approaches. Dr. Ibrahim serves on multiple committees of the Center for International Blood and Marrow Transplant Research related to cellular therapy and their toxicities, acute leukemia, and lymphoproliferative disorders.
Dr. Ibrahim is on Twitter at @uroosaibrahim
Language
Position
ASSISTANT PROFESSOR | Medicine, Hematology and Medical OncologyHospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
About Me
Uroosa Ibrahim, MD, is Assistant Professor of Medicine (Hematology and Medical Oncology) and Associate Medical Director of the Cellular Therapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. She is Medical Director of the Bone Marrow Transplant Unit and serves as a member of the Bone Marrow Transplant Disease Focus Group at The Tisch Cancer Institute.
Dr. Ibrahim’s clinical and research focus is on cellular therapy (CAR T cell therapy) and optimization of allogeneic stem cell transplant for the management of patients with hematologic malignancies. She is the site principal investigator for numerous multi-center clinical trials studying new therapeutic approaches. Dr. Ibrahim serves on multiple committees of the Center for International Blood and Marrow Transplant Research related to cellular therapy and their toxicities, acute leukemia, and lymphoproliferative disorders.
Dr. Ibrahim is on Twitter at @uroosaibrahim
Language
Position
ASSISTANT PROFESSOR | Medicine, Hematology and Medical OncologyHospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
Clinical Focus
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Adult Non-Hodgkin's Lymphoma
- Autologous Transplant for Multiple Sclerosis
- Benign Hematology
- Bone Marrow Transplantation, Allogeneic
- Bone Marrow Transplantation, Autologous
- CAR T Cell Therapy
- Cellular Therapy for Lymphoma
Show More
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Adult Non-Hodgkin's Lymphoma
- Autologous Transplant for Multiple Sclerosis
- Benign Hematology
- Bone Marrow Transplantation, Allogeneic
- Bone Marrow Transplantation, Autologous
- CAR T Cell Therapy
- Cellular Therapy for Lymphoma
- Cellular therapy for Acute Lymphoid Leukemia
- Chimeric Antigen Receptor Therapy
- Leukemia
- Lymphoma
- Myelodysplastic Syndromes
- Transplantation
Education
MBBS, Ziauddin Medical College
Residency, Internal Medicine
Staten Island University Hospital
Fellowship, Hematology/Oncology
Staten Island University Hospital
Fellowship, Bone Marrow Trans.
The Mount Sinai Hospital
Certifications
Medical Oncology
Hematology
American Board of Internal Medicine
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Ibrahim did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Doctors
Accepting New Patients
